0001209191-23-050332.txt : 20230921
0001209191-23-050332.hdr.sgml : 20230921
20230921210203
ACCESSION NUMBER: 0001209191-23-050332
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230920
FILED AS OF DATE: 20230921
DATE AS OF CHANGE: 20230921
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Liptak Len
CENTRAL INDEX KEY: 0001956842
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-41567
FILM NUMBER: 231270087
MAIL ADDRESS:
STREET 1: 124 SUNHAVEN RD
CITY: DANVILLE
STATE: CA
ZIP: 94506
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ProSomnus, Inc.
CENTRAL INDEX KEY: 0001934064
STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 5675 GIBRALTAR AVENUE
CITY: PLEASANTON
STATE: CA
ZIP: 94588
BUSINESS PHONE: 844-537-5337
MAIL ADDRESS:
STREET 1: 5675 GIBRALTAR AVENUE
CITY: PLEASANTON
STATE: CA
ZIP: 94588
FORMER COMPANY:
FORMER CONFORMED NAME: LAAA Merger Corp.
DATE OF NAME CHANGE: 20220615
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2023-09-20
0
0001934064
ProSomnus, Inc.
OSA
0001956842
Liptak Len
5675 GIBRALTAR AVENUE
PLEASANTON
CA
94588
1
1
0
0
Chief Executive Officer
0
Series A Preferred Stock
1.00
2023-09-20
4
A
0
50
A
2023-09-20
Common Stock
50000
50
D
Warrants (right to buy)
1.00
2023-09-20
4
A
0
50000
A
2028-09-20
Common Stock
50000
50000
D
The Series A Preferred Stock is convertible (subject to certain conversion limitations prior to the Issuer obtaining stockholder approval of the transactions contemplated by the SPA) into Common Stock at the Reporting Person's election at $1 per share, which conversion price may be adjusted in accordance withe the terms of the Series A Preferred Stock, and has no expiration date.
The Reporting Person acquired the shares and warrants pursuant to the terms of that certain Securities Purchase Agreement by and among the Issuer and the investors named therein, as disclosed in the Current Report on Form 8-K filed by the Issuer with the SEC on September 21, 2023 (the "SPA").
The warrants become exercisable upon the Issuer obtaining shareholder approval of the transactions contemplated by the SPA.
/s/ Brian B. Dow, Attorney-in-fact
2023-09-21